Academic Journal
THU0244 3 YEAR FOLLOW UP OF AN AT-RISK CONNECTIVE TISSUE DISEASE COHORT: ANALYSIS OF CLINICAL, GENE EXPRESSION AND FLOW CYTOMETRIC BIOMARKERS
| العنوان: | THU0244 3 YEAR FOLLOW UP OF AN AT-RISK CONNECTIVE TISSUE DISEASE COHORT: ANALYSIS OF CLINICAL, GENE EXPRESSION AND FLOW CYTOMETRIC BIOMARKERS |
|---|---|
| المؤلفون: | Hassan, S. U., Wigston, Z., Psarras, A., Dutton, K., MD Yusof, M. Y., Vital, E. |
| المصدر: | Annals of the Rheumatic Diseases ; volume 79, issue Suppl 1, page 349.1-349 ; ISSN 0003-4967 1468-2060 |
| بيانات النشر: | BMJ |
| سنة النشر: | 2020 |
| الوصف: | Background: We previously reported results from the first 118 “At-Risk” of autoimmune connective tissue disease (AI-CTD) individuals (i.e. ANA positivity, non-specific symptoms of ≤1 year and treatment naïve). At 1 year, 16% progressed to meet classification criteria for an AI-CTD. This was predicted by high baseline interferon (IFN) Score B and family history of RMD[1]. However, some may have progressed at later time points, or had clinically significant disease despite not meeting diagnostic criteria. Longer term outcomes, baseline and follow up flow cytometry biomarkers were never reported. Objectives: (i)Describe detailed analysis of 3-year follow-up data of the At-Risk cohort (ii)Evaluate flow cytometric biomarkers as predictors of these outcomes (iii)Analyse follow up biomarkers Methods: We conducted a prospective observational longitudinal study of At-Risk individuals in Leeds (n=150). Patients were assessed at baseline, then annually for 3 years. Depending on diagnostic criteria and need for therapy, patients were grouped as follows: Absolute non-progressors (no clinical diagnostic criteria) Undifferentiated CTD (U-CTD) (≥1 clinical criteria at baseline persisting at follow-up but not meeting criteria). This group was subdivided into those who required treatment with an immunosuppressant (IS) excluding antimalarials and those who did not Year 1 progressors (meeting criteria for an RMD by 1 year) Late progressors (meeting criteria for AI-CTD beyond 1 year follow-up). Bloods were analysed at baseline and 1 year for two IFN-stimulated gene expression scores previously described[2], monocytes and subsets of B and T cells using flow cytometry. Association between clinical criteria, biomarkers at baseline and long term outcomes were tested using ANOVA. Results: 3 year follow up data was available in 147/150 patients. Outcomes were: Absolute non-progressors: 63/147 (43%); U-CTD: 54/147 (37%); Year 1 progressors: 21/147 (14%) [SLE=18; pSS=3]; Late progressors (in years 1-2): 9/147 (6%) [SLE=7; pSS=2]. None ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1136/annrheumdis-2020-eular.3661 |
| الاتاحة: | http://dx.doi.org/10.1136/annrheumdis-2020-eular.3661 https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2020-eular.3661 |
| رقم الانضمام: | edsbas.1828D010 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/annrheumdis-2020-eular.3661 |
|---|